CD274 and neoplasm: (22), hyperprogression was defined as a Response Evaluation Criteria in Solid Tumors (RECIST) progression at the first evaluation and at least a two-fold increase of the tumor growth rate (TGR) upon prior anti-PD-1/PD-L1 therapy.